Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oritavancin in pediatric bacterial infections
NCT02134301Phase 1Completed
- Sponsor
- Melinta Therapeutics
- Start
- May 2014
- Primary completion
- Nov 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of oritavancin in Gram-positive bacterial infection, sponsored by Melinta Therapeutics. Primary endpoint: Area Under the Plasma Concentration Time-Curve at 168 hours. Started May 2014; status: completed.
02
Drugs
oritavancin
03
Conditions
Gram-positive bacterial infection
Beyond the preview
Go deeper on NCT02134301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02134301.